期刊
EXPERT OPINION ON DRUG SAFETY
卷 6, 期 2, 页码 207-215出版社
INFORMA HEALTHCARE
DOI: 10.1517/14740338.6.2.207
关键词
ALT; AST; cardiotoxicity; clara cell protein; diabetes; GLDH; glutathione S-transferase; hepatotoxicity; Histomics; NAG; nephrotoxicity; proteomics; pulmonary toxicity; RPA-1; sorbitol dehydrogenase; troponin
Histopathology is the gold standard when defining toxicological effects, but it is invasive, time consuming and expensive. Using biomarkers linked to distinct, defined cell types and tissues may provide a direct link to histopathology without its drawbacks and it also provides increased sensitivity and specificity. Furthermore, as histological testing is often impractical in human subjects, using biomarkers with a known histological distribution may fill the need of localising toxic injury to distinct organs or tissues. This paper discusses how, by using biomarkers with a known cellular origin (histologically defined biomarkers), toxic effects may be found earlier and at lower doses of compound, leading to potential savings in drug development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据